Orris

Latest guidelines for management of hypertension in pregnancy

Reading File
Finding Sources
Finding Sources
Reading File
Reading File
Reading File
Reading File
Reading File
Loading Image
Here is a comprehensive summary of current guidelines for the management of hypertension in pregnancy, drawn from multiple authoritative textbooks.

Management of Hypertension in Pregnancy

Classification

Hypertension in pregnancy is defined as BP ≥140/90 mm Hg on at least two separate occasions and complicates up to 10% of pregnancies. There are four categories:
CategoryDefinition
Chronic hypertensionPre-existing or diagnosed before 20 weeks; does not resolve postpartum
Gestational hypertensionNew-onset after 20 weeks, no proteinuria, resolves within 3 months of delivery
PreeclampsiaNew-onset hypertension after 20 weeks + proteinuria or end-organ damage
Superimposed preeclampsiaPreeclampsia developing on a background of chronic hypertension

Blood Pressure Targets

  • Severe hypertension (SBP ≥160 or DBP ≥105–110 mm Hg): drug therapy is clearly and urgently indicated to prevent stroke and cardiovascular complications.
  • Mild-to-moderate hypertension: The CHIPS trial (multicenter RCT) showed that treating to a tight target (DBP 85 mm Hg) versus less-tight (DBP 100 mm Hg) had no difference in adverse fetal outcomes, but the tight-control group had fewer episodes of severe hypertension. Treating to <140/90 mm Hg reduces risk of severe preeclampsia features, indicated preterm birth, and placental abruption without increasing SGA risk. — Creasy & Resnik's Maternal-Fetal Medicine
  • Non-pharmacologic measures (exercise, dietary sodium restriction, weight loss) have not been adequately evaluated in pregnant women and are not recommended as primary interventions.

Antihypertensive Drug Therapy

Chronic Hypertension: First-Line Oral Agents

DrugNotes
Labetalolα/β-blocker; preferred over pure β-blockers due to beneficial α-blockade effect on uteroplacental flow; multiple daily dosing
Long-acting NifedipineOnce-daily slow-release preparation; mild edema as side effect
α-MethyldopaCentrally acting; most extensive safety data, including 7-year neurological follow-up in exposed children; sedation and short duration of action

Second-Line Oral Agents

  • Metoprolol (long-acting formulation), Verapamil, Diltiazem — limited data but no proven fetal harm

Drugs to Avoid

  • Atenolol — associated with fetal growth restriction
  • Diuretics — theoretically impair the pregnancy-associated expansion of plasma volume; may be used cautiously for frank volume overload but contraindicated in preeclampsia

Contraindicated

  • ACE inhibitors and ARBs — second-trimester exposure causes fetal renal dysplasia, oligohydramnios, and pulmonary hypoplasia

Acute/Urgent BP Control (Severe Hypertension)

For SBP ≥160 or DBP ≥105–110 mm Hg, IV or rapid-acting agents are used:
AgentNotes
IV LabetalolGood safety data; first-line IV agent
IV NicardipineExtensive safety data as a tocolytic; effective
Hydralazine (IV/IM)Extensive clinical experience but increased risk of maternal hypotension and possibly placental abruption; now considered second-line
Oral nifedipine (immediate release)Effective for acute lowering
A meta-analysis of 21 trials showed hydralazine was associated with a higher risk of maternal hypotension compared to labetalol or nifedipine for acute management. — Brenner & Rector's The Kidney
Avoid: Sodium nitroprusside (risk of fetal cyanide toxicity if used >4 hours)

Preeclampsia Management

Severe Features Criteria

  • SBP ≥160 mm Hg or DBP ≥110 mm Hg
  • Headache or visual changes
  • Epigastric/right upper quadrant pain
  • Pulmonary edema
  • Platelets <100,000/µL
  • Creatinine >1.1 mg/dL
  • AST >2× the upper limit of normal

Management Flowchart

Management strategy for preeclampsia — flowchart by gestational age and severity
Modified from ACOG Task Force on Hypertension in Pregnancy — Creasy & Resnik's Maternal-Fetal Medicine

Key Decision Points

  • Absolute indications for immediate delivery: Eclampsia, stillbirth/nonviable fetus, pulmonary edema, DIC, non-reassuring fetal status, uncontrollable severe hypertension
  • ≥37 weeks + no severe features: Deliver
  • <37 weeks + no severe features: Expectant management with antenatal corticosteroids if appropriate; monitor with at least weekly BP, labs (CBC, AST, creatinine), NST/BPP twice weekly, AFI weekly, growth scans every 3 weeks
  • Delivery at 37 weeks if no complications arise

Seizure Prophylaxis

Magnesium sulfate is the agent of choice for eclampsia prophylaxis and treatment in severe preeclampsia.

Monitoring for Superimposed Preeclampsia

All women with chronic hypertension should be closely followed throughout pregnancy with:
  • Serial BP measurements
  • Urine protein monitoring
  • Serum creatinine baseline and repeat testing
  • Fetal growth scans (IUGR risk ~17%)

Postpartum Considerations

Women with gestational hypertension and preeclampsia are at increased long-term risk for hypertension and cardiovascular disease and should receive cardiovascular risk counselling postpartum.
Sources: Creasy & Resnik's Maternal-Fetal Medicine, 9e | Brenner & Rector's The Kidney, 11e | NKF Primer on Kidney Diseases, 8e | Comprehensive Clinical Nephrology, 7e
This is a shared conversation. Sign in to Orris to start your own chat.